Jnj-77242113

• A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting
  2024-515706-77-00 Phase III 8 countries Janssen Cilag International
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting
  2023-507039-39-00 Phase III 6 countries Janssen - Cilag International
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting
  2023-505121-14-00 Phase III 6 countries Janssen - Cilag International
• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-experienced Participants with Active Psoriatic Arthritis Recruiting
  2024-517284-23-00 Phase III 9 countries Janssen Cilag International
• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended
  2023-509239-19-00 Phase III 7 countries Janssen Cilag International
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended
  2023-505120-59-00 Phase III 6 countries Janssen - Cilag International
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended
  2023-505122-34-00 Phase III 4 countries Janssen - Cilag International
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 Phase II 9 countries Janssen - Cilag International

Showing 1–8 of 8 trials